RYTM Stock Analysis Today
Updated Nov 12, 2026 · trends, key levels, insider activity and news
Is RYTM bullish or bearish today?
Daily trend: Uptrend (starting) — turns down below $85.38
SEPT signal: Accumulation · Strong Bullish
Research grade: A · fair value $74.05 (+30.6%)
RYTM trend by timeframe
| Daily | Uptrend (starting) |
|---|---|
| 4 hour | Leaning Bearish |
| 1 hour | Bearish |
| 15 min | Strong Bearish |
| 5 min | Ascending Triangle |
Trends are calculated from price structure and update during market hours.
RYTM support and resistance levels
Resistance (above)
$114.755 touches
$122.201 touches
Support (below)
$106.5713 touches
$101.041 touches
$95.5927 touches
Upside zones: $117.78 / $120.03 / $122.27
See all levels on the live chart →Insider and institutional activity
Insiders
Sell30-day buys / sells
0 / 830-day net
—Hedge fund holders
259Latest RYTM news and filings
- DealFiscal.ai
Rhythm Pharmaceuticals rises after report of another bidder
A report says an additional bidder has emerged for Rhythm Pharmaceuticals. The news lifted the stock, though no details on the bidder or terms were given.
- AnalystBenzinga
Guggenheim keeps Buy rating on Rhythm Pharmaceuticals, lifts target to $147
Guggenheim repeated its Buy call on Rhythm Pharmaceuticals and moved its price target up to $147. The change reflects the firm's updated view on the stock.
- DealFiscal.ai
AstraZeneca makes $10 billion buyout offer for Rhythm Pharmaceuticals
AstraZeneca has put forward a $10 billion bid to take over Rhythm Pharmaceuticals. If completed, the two drugmakers would combine.
- DealFiscal.ai
AstraZeneca offers $10 billion to acquire Rhythm Pharmaceuticals
AstraZeneca has made a takeover bid worth $10 billion for Rhythm Pharmaceuticals. The offer would combine the two drugmakers if accepted.
- DealBenzinga
AstraZeneca reportedly bids $10 billion for Rhythm Pharmaceuticals
AstraZeneca has reportedly proposed paying $10 billion to acquire Rhythm Pharmaceuticals, a company focused on metabolic conditions and severe obesity. The report gives no outcome for the approach.
- ProductFiscal.ai
Rhythm Pharmaceuticals says mid-stage trial of bivamelagon succeeded
Rhythm Pharmaceuticals reported that a Phase 2 study of its drug bivamelagon met with success. No further details were given in the announcement.
- LegalFiscal.ai
UK Body Backs IMCIVREE for Adults With Bardet-Biedl Syndrome
A UK health assessment body has recommended IMCIVREE for adults living with Bardet-Biedl syndrome. The decision supports access to the therapy for this adult patient group.
- AnalystBenzinga
Citizens keeps Market Outperform on Rhythm Pharmaceuticals, lifts target to $166
Citizens repeated its Market Outperform rating on Rhythm Pharmaceuticals and raised its price target to $166. The update reflects the firm's current view on the stock.
Live RYTM chart with trend icons on every timeframe, key levels, dark pool and options flow, news alerts, and Ask GOAX for a full analysis on demand.
Start free 7-day trialFrequently asked questions
Why did RYTM stock move on Nov 3, 2026?
Nov 3, 2026: Rhythm Pharmaceuticals shares closed at $86.44, up 1.90% on heavy volume of over 7 million shares, after the drugmaker reported a narrower-than-expected quarterly loss and revenue that topped forecasts. The company also announced an amendment to its bivamelagon license agreement and raised $750 million in financing, a bullish development that could support future growth.
Is RYTM bullish or bearish today?
RYTM daily trend: Uptrend (starting) — turns down below $85.38. SEPT signal: Accumulation (Strong Bullish). Updated Nov 12, 2026.
What is RYTM's trend on each timeframe?
Daily: Uptrend (starting); 4 hour: Leaning Bearish; 1 hour: Bearish; 15 min: Strong Bearish; 5 min: Ascending Triangle.
What are RYTM support and resistance levels?
Support: $106.57, $101.04, $95.59. Resistance: $114.75, $122.20. Last price $110.07.
Are insiders buying or selling RYTM?
Insider signal: Sell. Last 30 days: 0 buys, 8 sells. 259 hedge funds hold RYTM.
What is the latest news on RYTM?
Nov 6, 2026: Rhythm Pharmaceuticals rises after report of another bidder · Nov 5, 2026: Guggenheim keeps Buy rating on Rhythm Pharmaceuticals, lifts target to $147 · Nov 5, 2026: AstraZeneca makes $10 billion buyout offer for Rhythm Pharmaceuticals